Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
NVAX 
Novavax Inc (NVAX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: NVAX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.67
1 Year Target Price $12.67
| 3 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -80.33% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.07B USD | Price to earnings Ratio 3.27 | 1Y Target Price 12.67 |
Price to earnings Ratio 3.27 | 1Y Target Price 12.67 | ||
Volume (30-day avg) 7 | Beta 2.31 | 52 Weeks Range 5.01 - 11.55 | Updated Date 12/14/2025 |
52 Weeks Range 5.01 - 11.55 | Updated Date 12/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.01 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 32.1% | Operating Margin (TTM) -112.68% |
Management Effectiveness
Return on Assets (TTM) 18.01% | Return on Equity (TTM) -898.2% |
Valuation
Trailing PE 3.27 | Forward PE 2.58 | Enterprise Value 555864397 | Price to Sales(TTM) 1 |
Enterprise Value 555864397 | Price to Sales(TTM) 1 | ||
Enterprise Value to Revenue 0.52 | Enterprise Value to EBITDA 1.36 | Shares Outstanding 162498995 | Shares Floating 134905041 |
Shares Outstanding 162498995 | Shares Floating 134905041 | ||
Percent Insiders 8.75 | Percent Institutions 61.24 |
About Novavax Inc
Exchange NASDAQ | Headquaters Gaithersburg, MD, United States | ||
IPO Launch date 1995-12-05 | President, CEO & Director Mr. John Charles Jacobs M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 952 | Website https://www.novavax.com |
Full time employees 952 | Website https://www.novavax.com | ||
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.